Santen Pharmaceutical Co., Ltd.
SNPHY · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $549,644,432 | $569,577,203 | $485,874,847 | $548,833,157 |
| - Cash | $63,560,000 | $84,578,000 | $92,997,000 | $77,851,000 |
| + Debt | $241,223 | $0 | $34,229,000 | $0 |
| Enterprise Value | $486,325,655 | $484,999,203 | $427,106,847 | $470,982,157 |
| Revenue | $468,849 | $68,737,000 | $77,231,000 | $76,369,000 |
| % Growth | -99.3% | -11% | 1.1% | – |
| Gross Profit | $256,401 | $37,118,000 | $46,096,000 | $42,234,000 |
| % Margin | 54.7% | 54% | 59.7% | 55.3% |
| EBITDA | $103,681 | $12,070,000 | $18,485,000 | $15,830,000 |
| % Margin | 22.1% | 17.6% | 23.9% | 20.7% |
| Net Income | $54,668 | $5,878,000 | $8,791,000 | $8,693,000 |
| % Margin | 11.7% | 8.6% | 11.4% | 11.4% |
| EPS Diluted | 0.16 | 17.28 | 25.69 | 25.22 |
| % Growth | -99.1% | -32.7% | 1.9% | – |
| Operating Cash Flow | $40,111 | $53,429 | $18,890,000 | $13,730,000 |
| Capital Expenditures | -$10,504 | -$12,845 | -$927,000 | -$3,056,000 |
| Free Cash Flow | $29,607 | $40,584 | $17,963,000 | $10,674,000 |